Lyka Labs

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: INE933A01014
  • NSEID: LYKALABS
  • BSEID: 500259
INR
79.19
-1.85 (-2.28%)
BSENSE

Dec 05

BSE+NSE Vol: 32.15 k

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About Lyka Labs Ltd stock-summary
stock-summary
Lyka Labs Ltd
Micro Cap
Pharmaceuticals & Biotechnology
Initially manufacturing formulations, Lyka Labs Limited brought bulk drugs into its operational fold by amalgamating Lyphin Chemicals Pvt Ltd with itself in Apr. '83. It also added a range of ayurvedic and animal health care products over the years. In 1990, it diversified into marketing medical and diagnostic equipment and instruments of Bekton Dickinson, US; Airsep Corporation, US; Coloplast, Denmark; and Terumo Corporation, Japan. Lyka Exports is the subsidiary of the company.
Company Coordinates stock-summary
Company Details
4801/B & 4802/A, GIDC Industrial Estate Ankleshwar Gujarat : 393002
stock-summary
Tel: 91-02646-221422/220549
stock-summary
companysecretary@lykalabs.com
Registrar Details
Sharex Dynamic (India) Pvt Ltd , Unit -1, Luthra Ind. Premises , Safed Pool, Andheri-Kurla Road, Andheri (E), Mumbai
stock-summary Capital Structure
Capital Structure stock-summary
Present Equity Capital
INR 35.69 Cr
Number of Shares
3.57 Cr
Face Value
INR 10.0
Date
Number
of Shares(Cr)
Equity
Capital (Rs Cr)
Shares Added
Face Value (Rs)
Reason
16-Apr-2024
3.57
35.69
2600000
10
Conversion of Warrants
18-Apr-2023
3.31
33.09
2400000
10
Conversion of Warrants
15-Mar-2023
3.07
30.69
2000000
10
Preferential Issue Of Shares
09-Aug-2019
2.87
28.69
550000
10
Conversion of Warrants
16-Aug-2017
2.81
28.14
6100000
10
Allotment of Equity To Others
16-Aug-2017
2.81
28.14
6100000
10
Allotment of Equity To Others
02-Nov-2015
2.2
22.04
460000
10
Allotment of Equity Shares To Promoter & Others
02-Nov-2015
2.2
22.04
460000
10
Allotment of Equity Shares To Promoter & Others
11-Jun-2008
2.16
21.58
650000
10
Conversion of Warrants
11-Jun-2008
2.16
21.58
650000
10
Conversion of Warrants
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Promoters

Pledged Promoter Holdings

None

Mutual Funds

Held by 4 Schemes (0.01%)

FIIs

Held by 5 FIIs (0.18%)

Promoter with highest holding

Ipca Laboratories Limited (40.98%)

Highest Public shareholder

Thermo Capital Private Limited (1.68%)

Individual Investors Holdings

31.52%

stock-summary Board of Directorsstock-summary
stock-summary
Management
Designation
Remuneration
KUNAL NARENDRA GANDHI
Chairman & MD & CEO
1.52 cr
Sandeep P Parikh
Non-Exec. & Independent Dir.
3.2 lacs
Yogesh B Shah
Executive Director & CFO
20.8 lacs
Dhara P. Shah
Non-Exec. & Independent Dir.
2.7 lacs
Kishore P Shah
Company Sec. & Compli. Officer
0
Babulal Jain
Independent Director
2.1 lacs
Prashant Godha
Director
1.8 lacs
Shashil Mendonsa
Director
1.5 lacs
stock-recommendationRaw Materials
Raw Materials Dashboard stock-summary
Raw Materials
Amount(Rs Cr)
% of RM Cost
 
Icon
No Data Available
stock-recommendation Finished Goods
Finished Goods Dashboard stock-summary
Finished Goods
Amount(Rs Cr)
% of Sales Turnover
Royalty
0.32
0.77%
 
0.77
Royalty
99.23
Royalty
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
37 Cr
(Quarterly Results - Sep 2025)
Net Profit:
-3 Cr
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

INR 283 Cr (Micro Cap)

stock-summary
P/E

141.00

stock-summary
Industry P/E

34

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

0.30

stock-summary
Return on Equity

2.02%

stock-summary
Price to Book

2.84